Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE says final no to Yondelis for ovarian cancer despite patient access scheme

This article was originally published in Scrip

Executive Summary

NICE, the health technology appraisal body for England and Wales, has today published final guidance rejecting PharmaMar's Yondelis (trabectedin), to be used in combination with pegylated liposomal doxorubicin hydrochloride, for treating National Health Service patients with relapsed platinum-sensitive ovarian cancer.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC012733

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel